Corporate Banner
Satellite Banner
Technology Networks Header
Friday, January 30, 2015
 
Register | Sign in
Home Page > Videos > Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
  Videos

Return

Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
SELECTBIO

The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration, without secondary effects to healthy tissues. In order to remediate to this problem, we investigated if the conjugation of the polypropylenimine dendrimer to transferrin, whose receptors are overexpressed on numerous cancers, could result in a selective gene delivery to tumours after intravenous administration, leading to an increased therapeutic efficacy. The objectives of this study are to evaluate the targeting and therapeutic efficacies of a novel transferrin-bearing polypropylenimine dendrimer. The intravenous administration of transferrin-bearing polypropylenimine polyplex resulted in gene expression mainly in the tumours. Consequently, the intravenous administration of the delivery system complexed to a therapeutic DNA encoding TNF led to a rapid and sustained tumour regression over one month (90% complete response, 10% partial response on A431 human epidermoid tumours). It also resulted in tumour suppression for 60% of PC-3 and 50% of DU145 prostate tumours. The treatment was well tolerated by the animals, with no apparent signs of toxicity. Transferrin-bearing polypropylenimine is therefore a highly promising delivery system for cancer therapy

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
New Method For Identifying Most Aggressive Childhood Cancers
A research group at Lund University in Sweden has found a new way to identify the most malignant tumours in children. The method involves studying genetic ‘micro-variation’, rather than the presence of individual mutations.
Powerful Tool Promises To Change The Way Scientists View Proteins
Aquaria, a publicly available web resource that streamlines and simplifies the process of gleaning insight from 3D protein structures, is fast, easy-to-use and contains twice as many models as all other similar resources combined.
Rapid Test Kit Detects Dengue Antibodies from Saliva
IBN’s MedTech innovation simplifies diagnosis of infectious diseases.
“Unprecedented Sensitivity and Specificity” in Ovarian Cancer
Study of the use of the Parsortix system as a clinical application in the detection and treatment of ovarian cancer patients.
Nanoparticle Lights Up Artery-Clogging Plaque
A new imaging agent that may light up dangerous plaque in arteries is to be evaluated in a clinical trial.
Study Uncovers Range of Molecular Alterations in Head and Neck Cancers
TCGA tumor genome sequencing analyses offer new insights into the effects of HPV and smoking, and find genomic similarities with other cancers.
Beating The Clock: New Treatment For Rabies Developed
University of Georgia researchers have developed a new treatment for rabies.
New Cells May Help Treat Diabetes
UI group creates insulin-producing cells that normalize blood-sugar levels in diabetic mice.
NIH Launches Tool to Advance Down Syndrome Research
Web portal will help approved professionals to plan clinical studies.
Cancer-Causing Virus Blocks Human Immune Response
Epstein-Barr virus shown to outwit the human immune response using microRNAs.
Scroll Up
Scroll Down
Skyscraper Banner
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn